Pre-exposure prophylaxis, or PrEP, is a new HIV prevention method in which people who do not have HIV infection take a pill daily to reduce their risk of becoming infected. The pill contains medicines that prevent HIV from making new virus as it enters the body. In this way PrEP medicines can help keep the virus from establishing a permanent infection.

Providing a preventive medication before exposure to a germ or virus is not a new practice and has been used to prevent other diseases. For example, when individuals travel to an area where malaria is common, they are advised to take malaria medication before and during travel to prevent getting infected if bitten by a mosquito carrying the malaria parasite. However, the use of medication to prevent HIV infection has only recently been evaluated. When used consistently, PrEP has been shown to reduce the risk of HIV infection among adult men and women at very high risk for HIV infection through sex or injecting drug use.

For some individuals at very high risk for HIV, PrEP may represent a much-needed additional prevention method — but it will not be right for everyone. PrEP is an intensive approach that requires strict adherence to daily medication and regular HIV testing. It is not intended to be used in isolation, but rather in combination with other HIV prevention methods. If it is used effectively and by persons at very high risk, PrEP may play a role in helping to reduce the number of new HIV infections in the United States.

PrEP Medications
Most PrEP efficacy trials have tested a combination of the antiretroviral drugs tenofovir disoproxil fumarate (also called TDF, or tenofovir) and emtricitabine (also called FTC), taken in a single pill daily for HIV prevention. This combination pill (brand name Truvada®) was approved by the U.S. Food and Drug Administration (FDA) for use as an HIV treatment in 2004, and was approved as PrEP in July 2012. Several clinical studies have also evaluated the use of tenofovir on its own as a preventive drug, but this drug alone is not FDA-approved as PrEP.

PrEP Proven Safe and Effective in Preventing Sexual HIV Acquisition
Strong research evidence indicates that PrEP, when used consistently, is safe and effective for reducing the risk of acquiring HIV sexually.

Research among Men Who Have Sex with Men
In November 2010, the multinational iPrEx study showed that a once-daily pill containing tenofovir plus emtricitabine was safe and reduced the risk of acquiring HIV by an average of 44 percent among men who have sex with men (MSM) overall.

The level of protection varied widely depending on how consistently participants used PrEP, with significantly greater levels of protection among those who adhered well to the daily dosing regimen. Among MSM with detectable levels of the medication in their blood, the risk of HIV acquisition was reduced by more than 90 percent.

The iPrEx study followed an earlier study by CDC that examined safety and adherence among MSM in the United States who were using daily tenofovir alone. The study found that the regimen was safe and did not lead to increases in risk behavior.
Research among Heterosexually-active Men and Women

In July 2011, researchers announced the results of two PrEP studies finding strong evidence that PrEP is effective and safe among heterosexually-active men and women.

- The TDF2 study found that a once-daily tablet containing tenofovir plus emtricitabine reduced the risk of acquiring HIV infection by roughly 62 percent overall in the study population of uninfected heterosexually-active men and women.
- The Partners PrEP study found that that daily doses of tenofovir plus emtricitabine or daily doses of tenofovir alone reduced HIV transmission among heterosexual serodiscordant couples (in which one partner is infected with HIV and the other is not) by 75 percent and 67 percent, respectively. The trial found that PrEP was equally effective among men and women, and that there was no statistically significant difference in efficacy between the two medication regimens.

As with the iPrEx study, both TDF2 and Partners PrEP showed that the level of protection offered by PrEP is strongly related to the level of adherence to the daily medication doses.

- In Partners PrEP, participants in the tenofovir-plus-emtricitabine group with detectable levels of the medication experienced a 90 percent reduction in risk for HIV infection; in the tenofovir-only group, the presence of medication in the blood was associated with an 86 percent reduction in risk.
- In TDF2, only half of the participants in the tenofovir-plus-emtricitabine group who became infected with HIV had any detectable medication in their blood, and even those participants had very low levels of medication present. This suggests that they had not taken PrEP consistently. In contrast, over 80 percent of matched participants who remained uninfected had detectable medication in their blood and the average medication level was substantially higher.

Two other research studies have also reported results of PrEP research among heterosexually-active women. The FEM-PrEP trial examined PrEP with tenofovir plus emtricitabine, and the VOICE trial examined PrEP with tenofovir plus emtricitabine and with tenofovir alone. Neither study showed that PrEP had a protective effect. Further sub-analyses showed that very few of those assigned to use the study drugs were actually taking their pills, indicating that lack of adherence was likely a major factor contributing to the lack of efficacy.

Other than low adherence, no factors have yet been identified that appear to influence the efficacy of PrEP in reducing sexual transmission of HIV.

Research among People Who Inject Drugs

In June 2013, the Bangkok Tenofovir Study, conducted by CDC, the Bangkok Metropolitan Administration and the Thailand Ministry of Public Health, reported that a once-daily tablet containing tenofovir reduced the risk of acquiring HIV by approximately 49 percent among men and women who inject drugs.

Consistent with prior research, participants who took the medication consistently had higher levels of protection. In an analysis of participants known to be adherent because they were observed taking their medication and had tenofovir detected in their blood, the risk of HIV acquisition was reduced by approximately 74 percent.

No studies conducted to date have identified any significant safety concerns associated with use of daily oral PrEP.

CDC Interim Guidance on PrEP Use

**MSM:** Following the publication of the iPrEx trial results, CDC published interim clinical guidance for physicians electing to provide PrEP for HIV prevention among MSM in January 2011. CDC guidance stressed the importance of targeting PrEP to MSM at very high risk for HIV acquisition; delivering PrEP as part of a comprehensive set of prevention services; providing counseling regarding risk reduction and the importance of PrEP medication adherence; ensuring MSM who are prescribed PrEP are confirmed to be HIV negative prior to use; and providing regular monitoring of HIV status, side effects, adherence, and risk behaviors.
**CDC Interim Guidance on HIV Pre-Exposure Prophylaxis**

### Before initiating PrEP

**Determine eligibility:**
- Document negative HIV antibody test immediately before starting PrEP medication.
- Test for acute HIV infection if patient has symptoms consistent with acute HIV infection or reports unprotected sex with an HIV-positive person in the preceding month.
- Determine if women are planning to become pregnant, are currently pregnant, or are breastfeeding.
- Confirm that patient is at ongoing, very high risk for acquiring HIV infection.
- If any sexual partner is known to be HIV-infected, determine whether receiving antiretroviral therapy; assist with linkage to care if not in care or not receiving antiretroviral therapy.
- Confirm that calculated creatinine clearance is ≥60 mL per minute (Cockcroft-Gault formula).

**Other recommended actions:**
- Screen for hepatitis B infection; vaccinate against hepatitis B if susceptible, or treat if active infection exists, regardless of decision regarding prescribing PrEP.
- Screen and treat as needed for sexually transmitted infections (STIs).
- Disclose to women that safety for infants exposed during pregnancy is not fully assessed but no harm has been reported.
- Do not prescribe PrEP to women who are breastfeeding.

### Beginning PrEP medication regimen:

- Prescribe tenofovir disoproxil fumarate 300 mg (TDF) plus emtricitabine 200 mg (FTC) (i.e., one Truvada [Gilead Sciences] tablet) daily.
- In general, prescribe no more than a 90-day supply, renewable only after HIV testing confirms that patient remains HIV-uninfected.
- For women, ensure that pregnancy test is negative or, if pregnant, that the patient has been informed about use during pregnancy.
- If active hepatitis B infection is diagnosed, consider using TDF/FTC, which may serve as both treatment of active hepatitis B infection and HIV prevention.

**Provide risk-reduction and PrEP medication-adherence counseling and condoms.**

**Prevention services provided for people who inject drugs receiving PrEP should include those targeting both injection and sexual risk behaviors.**

### Follow-up while PrEP medication is being taken:

- Every 2–3 months, perform an HIV antibody test (or fourth generation antibody/antigen test) and document negative result.
- At each follow-up visit for women, conduct a pregnancy test and document results; if pregnant, discuss continued use of PrEP with patient and prenatal-care provider.

### On discontinuing PrEP (at patient request, for safety concerns, or if HIV infection is acquired):

- Perform HIV test(s) to confirm whether HIV infection has occurred.
- If HIV positive, order and document results of resistance testing, establish linkage to HIV care.
- If HIV negative, establish linkage to risk reduction support services as indicated.
- If active hepatitis B is diagnosed at initiation of PrEP, consider appropriate medication for continued treatment of hepatitis B infection.
- If pregnant, inform prenatal-care provider of TDF/FTC use in early pregnancy and coordinate care to maintain HIV prevention during pregnancy and breastfeeding.

Recommendations in black apply to all adults at high risk for HIV infection; items in blue are specific to women; items in green are specific to people who inject drugs.
People Who Inject Drugs: In conjunction with the June 2013 publication of results from the Bangkok Tenofovir Study, CDC updated its interim guidance to recommend that providers who wish to prescribe PrEP to people who inject drugs follow the cautions and procedures in CDC’s existing interim clinical guidance on the use of PrEP to prevent sexual transmission, and that they deliver PrEP in combination with other proven prevention services to reduce both sexual and drug-related transmission risks.

Providers serving people who inject drugs should prescribe tenofovir plus emtricitabine, the PrEP regimen currently approved by FDA for the prevention of sexual HIV transmission. This combination pill contains the same amount of tenofovir that proved safe and effective in the Bangkok Tenofovir Study, can protect against sexual and drug-related risks, and has shown no additional toxicities compared to TDF alone either in PrEP trials or as part of treatment regimens among people who use drugs and are living with HIV.

CDC is also leading the development of comprehensive U.S. Public Health Service (PHS) guidelines on the use of PrEP for the prevention of HIV infection. These guidelines will include more detailed recommendations for PrEP use with adults at very high risk for HIV infection, including MSM, heterosexually-active men and women, and people who inject drugs. They are being developed in partnership with other PHS agencies and will incorporate input from providers, HIV prevention partners, and affected communities.

Next Steps in Assessing and Maximizing the Benefits of PrEP

PrEP offers a new tool to help combat the HIV epidemic among the hardest-hit populations in the United States and around the world, but its overall impact on the epidemic will depend on many things that at this point remain unknown, including access and acceptability among the populations at highest risk. Impact will also depend upon whether programs implemented in community settings can achieve the key requirements for success, including ensuring regular HIV testing, maintaining high levels of medication adherence, and preventing increases in risk behavior.

CDC and its partners are working to assess many of these key questions to determine how PrEP can most effectively be used in the United States.

- “Open-label extension” studies of the iPrEx, Partners PrEP, TDF2 and BTS trials — in which all participants in those trials are provided PrEP knowing that they are taking medication with proven efficacy — are planned or underway, and will provide additional valuable information in research settings about acceptability, adherence to PrEP, and risk behavior.
- Demonstration research projects to evaluate PrEP use among MSM are planned or underway in several California cities and Miami to provide similar information in “open-label” studies conducted with new research participants.
- An implementation pilot study will examine the practical requirements, costs, and impact of providing PrEP services to HIV-negative men and women at high risk for HIV at four federally-qualified health centers in the United States.
- CDC is working with federal, state, local, and private partners to identify additional ways to evaluate key PrEP implementation questions at community sites providing PrEP as a clinical HIV prevention service.

With limited resources available to combat the HIV epidemic, we will have to carefully consider how to most effectively use this tool in combination with other proven approaches to have the greatest possible impact on the HIV epidemic. Other key strategies such as HIV testing and treatment of individuals with HIV infection are critical, and will need to be expanded to reach the substantial number of Americans who are either unaware of their HIV status or not being effectively treated. CDC estimates indicate that only one-quarter of Americans with HIV currently have their virus suppressed to the levels needed to maintain their own health and prevent transmission to others.

Nevertheless, while expanded HIV treatment for those with HIV infection is essential, it will not be sufficient to end the epidemic. Even if we can improve treatment outcomes for all of those diagnosed with HIV, individuals who do not know they are infected are likely to continue to unknowingly transmit HIV infection to others.

With 2.7 million people becoming infected annually worldwide, including approximately 50,000 in the United States, we must capitalize on every available prevention tool. While the most appropriate uses of PrEP as part of these efforts is yet to be determined, available data suggest that this prevention method, if used strategically and effectively, could be cost-effective and may help reduce the continuing toll of HIV infection in this nation.